

If you are still having problems viewing this message, please [click here](#) for additional help.

Introducing Claire Danes... the new lashes behind

Latisse®
(bimatoprost ophthalmic solution) 0.03%



Important Safety Information

Contraindications:

LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.

Warnings and

Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) 0.03% or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (LUMIGAN®) was instilled directly onto the eye. Although iridal pigmentation was not reported in clinical studies with LATISSE®, patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to periocular pigmented tissues and eyelashes.

There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.

LATISSE® solution should be used with caution in patients

GET READY TO WELCOME CLAIRE DANES TO YOUR OFFICE!

Allergan is excited to announce Claire Danes as the new face for LATISSE® (bimatoprost ophthalmic solution) 0.03%, the *first* and *only* FDA-approved product indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.

Claire Danes is a highly accomplished film and TV actress who has starred in films such as *Shopgirl*, *Romeo + Juliet*, and, most recently, the critically-acclaimed HBO® movie, *Temple Grandin*. She joins Brooke Shields as the lashes behind LATISSE®.

SEE CLAIRE'S DRAMATIC RESULTS



Claire Danes without mascara—lashes not retouched.

Individual results may vary. By prescription only. Upon discontinuation of treatment, eyelash growth is expected to return to its pretreatment level.

Patients should be informed of the possibility of disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth.

If you no longer wish to receive e-mails from Allergan, Inc., about LATISSE® products, programs, and services, please [click here](#) to unsubscribe.

CLICK HERE
to learn more about
LATISSE®

START A CONVERSATION ABOUT LATISSE®

Be among the first to welcome Claire Danes to your office.

Talk to your Allergan Sales Representative about marketing materials featuring Claire for your practice.

For more information, contact your Allergan Sales Representative or call Allergan Customer Service at 1-800-377-7790.

with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.

Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.

[Click here](#) for full prescribing information.



©2010 Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 ® and ™ marks owned by Allergan, Inc. HBO is a registered trademark of Home Box Office, Inc. www.latisse.com APC32HR10 106135
ADVERTISEMENT